Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Catheter Precision, Inc. is a medical device company operating in the cardiac electrophysiology and interventional cardiology industries, with a primary focus on technologies that improve the diagnosis and treatment of complex heart rhythm disorders. The company designs and commercializes catheter-based solutions used by electrophysiologists to map, navigate, and ablate cardiac arrhythmias, particularly ventricular tachycardia. Its revenue is primarily derived from the sale of proprietary disposable medical devices used in hospital electrophysiology labs.
The company’s core product portfolio centers on advanced catheter navigation and mapping technologies intended to improve procedural precision, reduce fluoroscopy time, and enhance physician control during complex ablation procedures. Catheter Precision positions itself as a niche innovator targeting challenging arrhythmia cases rather than broad, high-volume electrophysiology procedures. The company was founded in 2012 and has evolved from early-stage technology development into limited commercial deployment, with a strategy focused on regulatory clearance, clinical adoption, and strategic partnerships within the electrophysiology ecosystem.
Business Operations
Catheter Precision generates revenue primarily through the commercialization of its VIVO™ system and Amigo™ Remote Catheter System, which are designed to assist physicians in planning and executing electrophysiology procedures. VIVO™ is a non-invasive cardiac mapping technology that uses patient imaging and ECG data to localize ventricular arrhythmia origins prior to invasive procedures, while Amigo™ enables remote robotic catheter manipulation to enhance procedural stability and operator safety.
Operations are conducted through a combination of in-house development and outsourced manufacturing, with sales efforts focused on direct engagement with hospitals and electrophysiology labs. The company operates principally in the United States, with early-stage international commercialization through distributors. Catheter Precision does not currently report large-scale joint ventures, but it maintains clinical collaborations with academic medical centers to support validation, physician training, and adoption of its technologies.
Strategic Position & Investments
Strategically, Catheter Precision is focused on expanding adoption of its core technologies within the ventricular tachycardia ablation market, which is considered a complex and underserved segment of electrophysiology. Growth initiatives include expanding physician awareness, increasing hospital installations, and pursuing additional regulatory clearances to broaden clinical indications. The company has emphasized disciplined capital deployment, prioritizing commercialization efficiency and clinical evidence generation.
The company has historically invested in research and development to refine its software-driven mapping capabilities and robotic navigation features. While Catheter Precision has not completed major acquisitions, it has invested internally in expanding the functionality of VIVO™ and improving integration with existing electrophysiology lab workflows. Emerging areas of focus include enhanced data analytics and workflow optimization tools designed to complement existing electrophysiology platforms rather than compete directly with large multinational device manufacturers.
Geographic Footprint
Catheter Precision is headquartered in Fort Lee, New Jersey, and its primary operational and commercial focus remains in North America. The United States represents the company’s largest market, driven by the concentration of advanced electrophysiology centers and favorable reimbursement structures for complex ablation procedures.
Internationally, the company has established a limited presence in Europe and select other regions through distributor relationships rather than direct subsidiaries. These markets are targeted opportunistically, with an emphasis on regulatory alignment and early clinical adopters. Overall, the company’s geographic footprint reflects its status as a small-cap medical device firm prioritizing depth in core markets over broad global expansion.
Leadership & Governance
Catheter Precision is led by an executive team with experience in medical devices, electrophysiology, and healthcare commercialization. The leadership emphasizes clinical collaboration, incremental innovation, and capital efficiency as guiding principles for long-term value creation. Governance follows a traditional public-company structure, with oversight provided by a board of directors that includes industry and financial expertise.
Key executives include:
- David Jenkins – Chief Executive Officer
- Gerard B. Condon – Chief Financial Officer
- Dr. David A. Smith – Chief Medical Officer
- John B. Mitchell – Vice President of Sales
The leadership team’s strategic vision centers on establishing Catheter Precision as a specialized technology partner for electrophysiologists addressing the most complex arrhythmia cases, while maintaining regulatory compliance and disciplined operational execution.